US Regulator Reviews Safety of Abortion Pill Mifepristone

The US Food and Drug Administration (FDA) is continuing to review the safety of mifepristone, a drug used in most medication abortions. According to a senior FDA official, the review has been underway for several months and results could be released in July.

The agency said the evaluation was scientifically based and focused on the drug's risk management system, dismissing claims that the research was only just beginning. According to the Wall Street Journal, the full review is expected to take six months.

Since Donald Trump returned to the presidency, pro-life organizations have called for stricter regulation of mifepristone and a return to in-person dispensing of the drug. They have cited a 2025 study finding that one in 10 women experienced serious health complications after taking the pill.

Carol Tobias, president of National Right to Life, welcomed the safety review and noted that under the Obama administration the requirement to report complications to the FDA had been significantly reduced.

Susan B. Anthony Pro-Life America also called on the administration to take further steps, including ending litigation over the mailing of abortion pills. The organization claims that thousands of women face serious side effects, including bleeding, infections and sepsis.

(ewtnnews, bak)